相似文献
1
Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).
J Clin Microbiol. 2009 Jun;47(6):1942-6. doi: 10.1128/JCM.02434-08. Epub 2009 Apr 22.
2
Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
J Antibiot (Tokyo). 2015 Sep;68(9):556-61. doi: 10.1038/ja.2015.29. Epub 2015 Apr 22.
3
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Diagn Microbiol Infect Dis. 2011 Jan;69(1):45-50. doi: 10.1016/j.diagmicrobio.2010.08.013.
4
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02045-16. Print 2017 Mar.
5
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00099-20.
6
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Antimicrob Agents Chemother. 2005 Feb;49(2):512-7. doi: 10.1128/AAC.49.2.512-517.2005.
7
International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).
J Clin Microbiol. 2006 May;44(5):1782-7. doi: 10.1128/JCM.44.5.1782-1787.2006.
8
Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00840-19. Print 2019 Aug.
9
Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00906-17. Print 2017 Oct.
10
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
J Antimicrob Chemother. 2016 Oct;71(10):2868-73. doi: 10.1093/jac/dkw214. Epub 2016 Jun 10.
引用本文的文献
1
The glyoxylate cycle and alternative carbon metabolism as metabolic adaptation strategies of Candida glabrata: perspectives from Candida albicans and Saccharomyces cerevisiae.
J Biomed Sci. 2019 Jul 13;26(1):52. doi: 10.1186/s12929-019-0546-5.
2
Candidemia in patients with prolonged fever in Kashan, Iran.
Curr Med Mycol. 2016 Sep;2(3):20-26. doi: 10.18869/acadpub.cmm.2.3.20.
3
Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study.
Infection. 2016 Dec;44(6):747-755. doi: 10.1007/s15010-016-0924-9. Epub 2016 Jul 11.
4
In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.
Jundishapur J Microbiol. 2015 Sep 8;8(9):e28057. doi: 10.5812/jjm.28057. eCollection 2015 Sep.
5
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality.
Intensive Care Med. 2015 Sep;41(9):1601-10. doi: 10.1007/s00134-015-3866-2. Epub 2015 May 19.
6
New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study.
BMC Infect Dis. 2015 Feb 28;15:108. doi: 10.1186/s12879-015-0840-0.
7
Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints.
Rev Inst Med Trop Sao Paulo. 2014 Nov-Dec;56(6):477-82. doi: 10.1590/s0036-46652014000600004.
8
Coriandrum sativum L. (Coriander) essential oil: antifungal activity and mode of action on Candida spp., and molecular targets affected in human whole-genome expression.
PLoS One. 2014 Jun 5;9(6):e99086. doi: 10.1371/journal.pone.0099086. eCollection 2014.
9
In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals.
Mycopathologia. 2014 Apr;177(3-4):143-56. doi: 10.1007/s11046-014-9738-4. Epub 2014 Mar 29.
10
Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013.
BMC Oral Health. 2014 Feb 20;14:14. doi: 10.1186/1472-6831-14-14.
本文引用的文献
1
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
2
In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.
J Clin Microbiol. 2008 Aug;46(8):2568-72. doi: 10.1128/JCM.00535-08. Epub 2008 Jun 18.
3
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.
J Clin Microbiol. 2007 Jul;45(7):2180-2. doi: 10.1128/JCM.00399-07. Epub 2007 May 2.
4
Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.
Diagn Microbiol Infect Dis. 2007 Jul;58(3):371-4. doi: 10.1016/j.diagmicrobio.2007.01.018. Epub 2007 Mar 26.
5
Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003).
Arch Pathol Lab Med. 2006 Jun;130(6):767-78. doi: 10.5858/2006-130-767-PAOAAA.
6
International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).
J Clin Microbiol. 2006 May;44(5):1782-7. doi: 10.1128/JCM.44.5.1782-1787.2006.
7
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
J Clin Microbiol. 2005 Nov;43(11):5425-7. doi: 10.1128/JCM.43.11.5425-5427.2005.
8
Initial results from a longitudinal international surveillance programme for anidulafungin (2003).
J Antimicrob Chemother. 2004 Dec;54(6):1051-6. doi: 10.1093/jac/dkh504. Epub 2004 Nov 25.
9
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
J Clin Microbiol. 2004 Aug;42(8):3475-82. doi: 10.1128/JCM.42.8.3475-3482.2004.
10
In vitro activity of anidulafungin against selected clinically important mold isolates.
Antimicrob Agents Chemother. 2004 May;48(5):1912-5. doi: 10.1128/AAC.48.5.1912-1915.2004.
Zotero 插件